Ganlai's FXR agonist ASC42 completes first patient dosing in US Phase I clinical trial New drug for cystic fibrosis! EC approves Sym ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback